Abstract: Thiaxozle, oxazole, imidazole, isoxazole and isoxazoline compounds of the formula wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is selected from the various optionally substituted aromatic radicals defined in the specification, B is hydrogen, alkyl or phenyl, R1 and R2 are independently hydrogen, alkyl or cycloalkyl or R1 and R2 taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members and ? is —NH46R47 or —OR48, R46 and R47 are independently hydrogen, alkyl, cycloalkyl or —(CH2)kCOOR51, R51 is alkyl or haloalkyl and R48 is hydrogen or alkyl having advantageous pharmacological properties which allow their use in therapeutics, for treating neurodegenerative disorders or pain.

Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S.

Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.

Abstract: The invention concerns a pharmaceutical composition comprising, as active principle, at least a calpain inhibiting substance and at least a substance trapping reactive oxygen species (ROS), and optionally an acceptable pharmaceutical carrier. The invention also concerns a product comprising at least a calpain inhibiting substance and at least a substance trapping reactive oxygen species (ROS), selectively or not, as combination product, the active principle being separate.

Abstract: The invention relates to a method for the purification of a clay that is intended for therapeutic use.

Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patent.

Abstract: The invention concerns a novel protein modulating cancer cell proliferation. The proteins encoded by the polynucleotides of the invention enable to determine the degree of malignity of abnormal cell proliferation.

Abstract: Compounds of the formula in racemic or enantiomeric forms wherein the substituents are as defined in the application. Useful for treating acromegalia, hypophyseal adenomas or endocrinic gastroenteropancreatic tumors.

Abstract: The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2 radical wherein R1 and R2 represent a hydrogen atom or an alkyl radical or R1 and R2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR3R4—, —O—, —S and NR5-radicals, R3 and R4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected

Abstract: Novel imidazole compounds of the formula wherein the substituents are as defined in the application having antitumoral activity and use thereof.

Abstract: Compounds of the formula wherein the substituents are as defined in the specification which are useful for the treatment of pain.

Abstract: The invention concerns the use of zinc derivatives of general formula (I) wherein: L1 represents a group of formula: —E14(R14)(R?14)(R?14), —E15(R15) (R?15) or —E16(R16); E is an atom of group 15; L2 and L3 independently represent a group of formula: —E14(R14)(R?14)(R?14), —E15(R15)(R?15) or —E16(R16), or together form a chain of formula —L?2—A—L?3—; A represents a saturated or unsaturated chain comprising one, two or three elements of group 14; L?2 and L?3 independently represent a group of formula —E14(R14)(R?14) —E15(R15) or —E16—; E14 is an element of group 14; E15 is an element of group 15; E16 is an element of group 16; R14, R?14, R?14, R15, R?15 and R16 represent various groups, as (co) polymerisation catalysts of cyclic esters

Abstract: A method of modulating, sodium channels in warm-blooded animals in need thereof by administering a compound of the formula Wherein the substituents are defined as in the specification and compounds of the formula wherein the substituents are as defined in the specification.

Abstract: A method of treating pain in a warm-blooded animal comprising administering to anwarm-blooded animal in need thereof an amount of a compound of the formula wherein the substituents are defined in accordance with the disclosure.

Abstract: A subject of the present invention is new compounds having a lanthanide and having a tridentate ligand, a process for their preparation and their use in particular as polymerization catalysts.

Abstract: The invention relates to a method for preparing polyesters A containing several mid-chain free acid functions by ring-opening polymerisation in the presence of a chain initiator: the benzyl diester of the tartaric acid, the phenyl radical of which is optionally substituted. A: aliphatic based on cyclic esters such as lactides and glycolides.

Abstract: A method of treating proliferative diseases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of at least one compound selected from the group consisting of mikanolide and dihydromikanolide sufficient to treat said disease.

Abstract: The use of stannylenes and germylenes of general formula (I) wherein: M represents a tin or geranium atom; L1 and L2 independently represent a group of formula: -E14(R14) (R?14) (R?14), -E15(R15) (R?15) or -E16(R16)) or together form a chain of formula -L?1-A- L?2; A represents a saturated or unsaturated chain comprising one, two or three elements of group 14; L?1 and L?2, represent, independently, a group of formula: -E14(R14) (R?14)-, E15(R15)- or -E16-; E14 is an element of group 14; E15 is an element of group 15; E16 is an element of group 16; R14, R?14, R?14, R15, R?15 and R16 represent variable groups as polymerization catalysts of heterocycles.